Signs of Low Testosterone in Menopause: Symptoms and Hormone Changes

When the conversation turns to menopause, estrogen typically takes center stage. Hot flashes, night sweats, vaginal dryness - these symptoms are well-recognized consequences of declining estrogen. But menopause involves a broader hormonal shift, and for many women, the decline in testosterone plays an equally significant - and often overlooked - role in how they feel.

The signs of low testosterone in menopause can overlap with, or compound, estrogen-related symptoms. For some women, persistent fatigue, loss of sexual desire, mood changes, and difficulty maintaining muscle strength may be driven primarily by declining androgen levels, not estrogen alone. Understanding this distinction is the first step toward more complete hormonal evaluation and care.

[banner1]

How Testosterone Changes During Menopause

Testosterone is not exclusively a male hormone. Women produce testosterone in the ovaries and adrenal glands throughout their reproductive years, and it plays important roles in energy, mood, libido, bone density, and muscle maintenance.

The decline in women's testosterone levels is gradual and begins well before menopause. A systematic review found that total testosterone falls by approximately 50% from peak levels by the time a woman reaches natural menopause, with the decline in free (biologically active) testosterone often more pronounced due to rising levels of sex hormone-binding globulin (SHBG) (Vlachos et al., Hormones (Athens), 2021). SHBG binds testosterone in the bloodstream, reducing the amount available to tissues; as SHBG increases with age, less free testosterone reaches androgen-sensitive cells even if total levels appear borderline-low.

Adrenal androgens - particularly dehydroepiandrosterone (DHEAS), a precursor converted to testosterone in peripheral tissues - also decline significantly with age, falling approximately 10–20% per decade from peak levels in the mid-20s (Vlachos et al., 2021).

Surgical menopause (following bilateral oophorectomy) produces a more abrupt androgen decline than natural menopause, as the ovaries are responsible for approximately 50% of a woman's testosterone production. Women who undergo oophorectomy before natural menopause often experience more severe androgen deficiency symptoms, and the evidence base for testosterone replacement is strongest in this group (Shifren et al., N Engl J Med, 2000).

Signs and Symptoms of Low Testosterone in Menopause

The symptom profile of androgen decline in menopause is distinct from - though often coexistent with - estrogen deficiency. Recognizing testosterone menopause symptoms requires understanding which symptoms are more androgen-specific.

Reduced sexual desire (hypoactive sexual desire disorder)

This is the most consistently documented sign of low testosterone in menopause. Multiple randomized controlled trials have demonstrated that women with surgical or natural menopause who report loss of libido show significant improvement with testosterone therapy, independent of estrogen status (Shifren et al., 2000; Achilli et al., Menopause, 2017). Reduced arousal, diminished frequency of satisfying sexual activity, and emotional disconnection from intimacy are all associated with androgen decline.

Persistent fatigue and reduced energy

Women experiencing fatigue that does not resolve with adequate sleep or rest may be experiencing androgen-related energy dysregulation. Testosterone contributes to mitochondrial function and metabolic energy production; its decline may contribute to the kind of persistent, unexplained tiredness that many menopausal women describe (Johansen et al., Acta Obstet Gynecol Scand, 2020).

Mood changes: low mood, anxiety, emotional flatness

Testosterone has neuroactive properties and influences dopaminergic and serotonergic signaling. Low testosterone in women over 50 is associated with increased rates of depressive symptoms, emotional blunting, and a loss of motivation or sense of well-being - distinct from the classic anxiety and irritability more associated with estrogen fluctuation.

Reduced muscle mass and increased body fat

Testosterone supports lean muscle maintenance through anabolic pathways. As androgen levels fall, women may notice progressive difficulty maintaining muscle tone and increasing body fat - particularly around the abdomen - even without significant changes in diet or activity. This shift in body composition affects both metabolic health and quality of life.

Cognitive symptoms: brain fog, difficulty concentrating

Some women report difficulty with memory, word-finding, and sustained concentration that they attribute to menopause. While estrogen is well-studied in cognitive aging, emerging evidence suggests androgens also influence neurological function and that their decline may contribute to cognitive changes (Vegunta et al., J Womens Health, 2020).

Bone density considerations

Testosterone contributes independently to bone mineral density through anabolic effects on bone formation. While estrogen replacement remains the primary intervention for postmenopausal bone loss, androgens play a supporting role, and their decline may partially contribute to accelerated bone loss in early menopause.

Testosterone Menopause Symptoms vs. Estrogen Deficiency Symptoms

Many menopausal symptoms are driven by estrogen decline: vasomotor symptoms (hot flashes, night sweats), genitourinary atrophy, and disrupted sleep. But some symptoms are more specifically associated with androgen deficiency.

More androgen-specific:

• Loss of sexual desire and arousal (not just pain with intercourse)
• Profound fatigue not explained by sleep disruption
• Loss of motivation and emotional vitality
• Declining muscle mass and strength

More estrogen-specific:

• Hot flashes and night sweats
• Vaginal dryness and genitourinary symptoms
• Sleep disruption linked to vasomotor events

Overlapping:

• Mood changes (both androgens and estrogens influence mood)
• Cognitive symptoms
• Bone density loss

Distinguishing the hormonal driver of specific symptoms matters because it influences which therapeutic approach is most appropriate. For women whose primary complaints are low libido, persistent fatigue, and loss of vitality - rather than vasomotor symptoms - androgen evaluation may be as clinically relevant as estrogen assessment.

Testing Testosterone Levels in Menopausal Women

Testing testosterone in women requires clinical context and careful interpretation. There is currently no universally agreed-upon threshold for diagnosing "low testosterone" in women - unlike the more established reference ranges for men.

Total vs. free testosterone: Total testosterone measures all circulating testosterone, including the majority that is bound to SHBG and albumin. Free testosterone - the biologically active fraction - is typically only 1–2% of total. In women with high SHBG (common with age and estrogen use), total testosterone may appear within the broad reference range while free testosterone is significantly reduced and clinically relevant.

Assay limitations: Standard immunoassay testosterone tests are calibrated for male physiological levels and are relatively imprecise at the low levels typical in women. Mass spectrometry-based testing provides greater accuracy for low-level female androgen measurement, though it is not widely available in routine clinical settings.

The Endocrine Society's 2014 guideline recommends against routine testosterone testing for women outside the clinical context of evaluating HSDD or other androgen-related symptoms, and notes that a low testosterone level alone does not establish a diagnosis of androgen deficiency in women (Wierman et al., JCEM, 2014).

What Evidence Says About Testosterone Therapy for Menopausal Women

The evidence base for testosterone therapy in postmenopausal women has strengthened considerably over the past two decades.

A 2019 systematic review and meta-analysis published in The Lancet Diabetes & Endocrinology analyzed data from 36 randomized controlled trials and concluded that testosterone therapy significantly improved sexual function in postmenopausal women, with the most consistent evidence for hypoactive sexual desire disorder (Islam et al., 2019). The review found no increased risk of serious adverse events from physiological dosing.

In the same year, the Global Consensus Position Statement on testosterone therapy for women - co-authored by experts from 11 international endocrine and gynecological societies - endorsed testosterone therapy for postmenopausal women with HSDD as evidence-based, while acknowledging that no testosterone formulation is currently approved by regulatory agencies for use in women (Davis et al., JCEM, 2019).

A meta-analysis of 8 randomized controlled trials specifically examining transdermal testosterone in postmenopausal women found significant improvements in sexual desire, arousal, orgasm, and pleasure compared to placebo, without increased risk of adverse events at physiological doses (Achilli et al., Menopause, 2017).

The Endocrine Society's 2014 clinical practice guideline indicates that testosterone therapy is appropriate for surgically menopausal women with HSDD after other contributing factors have been excluded, while noting insufficient evidence to routinely recommend it for naturally menopausal women (Wierman et al., 2014). Clinical practice continues to evolve as more data from naturally menopausal women accumulates.

Key Takeaways

• Signs of low testosterone in menopause include reduced sexual desire, persistent fatigue, mood changes, muscle loss, and cognitive fog - symptoms that may be distinct from estrogen-deficiency symptoms like hot flashes.
• Testosterone declines gradually from the mid-20s; by natural menopause, total levels have typically fallen ~50% from peak, with free testosterone declining even more due to rising SHBG.
• Testosterone menopause symptoms are particularly pronounced after surgical menopause (bilateral oophorectomy), where the decline is abrupt.
• Low testosterone in women over 50 is common but often unrecognized; there is currently no universally agreed-upon threshold for diagnosing deficiency in women.
• Multiple RCTs and meta-analyses support testosterone therapy for postmenopausal HSDD; the 2019 Global Consensus Statement from 11 international medical societies endorses its evidence-based use.
• Evaluation by an experienced clinician - assessing symptoms, hormone levels in context, and individual health profile - is essential before considering treatment.

Frequently Asked Questions

Is low testosterone common during menopause?

Yes. Total testosterone levels decline by approximately 50% from peak values by the time a woman reaches natural menopause, and the decline in free testosterone is often more pronounced due to rising SHBG (Vlachos et al., 2021). After surgical menopause involving oophorectomy, the decline is more abrupt, as the ovaries produce roughly half of a woman's testosterone.

What are the signs of low testosterone in menopause?

The most commonly reported signs of low testosterone in menopause include reduced sexual desire (the most consistently documented symptom), persistent fatigue, low mood or emotional flatness, decreased muscle mass, and in some women, cognitive symptoms such as brain fog or difficulty concentrating (Johansen et al., 2020; Vegunta et al., 2020).

Can low testosterone cause fatigue in menopause?

Evidence suggests it may. Testosterone contributes to energy metabolism and mitochondrial function, and its decline is associated with the kind of persistent, unrefreshing fatigue that some menopausal women describe - distinct from sleep-disrupted tiredness more typically linked to estrogen-driven vasomotor events.

How is low testosterone diagnosed in menopausal women?

There is no universally agreed-upon threshold for low testosterone in women. Testing typically involves measuring total and free testosterone, ideally using mass spectrometry for accuracy at low female levels. Results must be interpreted in clinical context: SHBG levels, symptoms, reproductive history, and other hormonal factors all inform whether a woman is likely experiencing androgen deficiency (Wierman et al., 2014).

Does testosterone therapy help with menopausal symptoms?

Evidence is strongest for hypoactive sexual desire disorder (HSDD). Multiple RCTs and a 2017 meta-analysis found that transdermal testosterone significantly improved sexual desire, arousal, orgasm, and pleasure in postmenopausal women (Achilli et al., 2017). The 2019 Global Consensus Statement endorsed testosterone for postmenopausal HSDD as evidence-based (Davis et al., 2019). Evidence for other symptoms such as fatigue and mood is more limited.

Is low testosterone in women over 50 the same as menopause?

Not exactly. Menopause is defined by the cessation of menstruation for 12 consecutive months and is primarily characterized by estrogen and progesterone decline. Low testosterone in women over 50 reflects the more gradual age-related androgen decline that begins earlier in life and continues through and after menopause. While the two processes often overlap and interact, they involve different hormones and may require different evaluation and treatment approaches.

What is the difference between low estrogen and low testosterone symptoms?

Estrogen deficiency more specifically causes hot flashes, night sweats, vaginal dryness, and sleep disruption. Testosterone deficiency is more specifically associated with loss of sexual desire and arousal (independent of genitourinary symptoms), persistent fatigue and low motivation, and declining muscle strength. Mood changes and cognitive symptoms may result from either or both hormonal shifts. Many menopausal women experience both, and clinical assessment should consider both hormones.

Should postmenopausal women test their testosterone levels?

Routine testing is not universally recommended. The Endocrine Society guideline suggests testosterone testing in the context of evaluating symptoms potentially attributable to androgen deficiency, particularly HSDD (Wierman et al., 2014). A qualified clinician can help determine whether testing is appropriate based on symptom profile, reproductive history, and overall health status.

Take the Next Step

Hormone optimization in menopause is not one-size-fits-all. If you are experiencing persistent fatigue, low libido, or mood changes that conventional menopausal care has not fully addressed, a comprehensive hormone evaluation may reveal whether androgen levels are contributing to your symptoms. At Humanaut Health, our clinicians take a personalized, evidence-based approach to hormone optimization - looking at the full hormonal picture, not just estrogen.

References

• Islam RM, Bell RJ, Green S, Page MJ, Davis SR. "Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data." Lancet Diabetes Endocrinol. 2019;7(10):754–766. DOI: 10.1016/S2213-8587(19)30189-5
• Davis SR, Baber R, Panay N, et al. "Global Consensus Position Statement on the Use of Testosterone Therapy for Women." J Clin Endocrinol Metab. 2019;104(10):4660–4666. DOI: 10.1210/jc.2019-01603
• Johansen N, Hirschberg AL, Moen MH. "The role of testosterone in menopausal hormone treatment. What is the evidence?" Acta Obstet Gynecol Scand. 2020;99(8):966–969. DOI: 10.1111/aogs.13819
• Shifren JL, Braunstein GD, Simon JA, et al. "Transdermal Testosterone Treatment in Women with Impaired Sexual Function after Oophorectomy." N Engl J Med. 2000;343(10):682–688. DOI: 10.1056/NEJM200009073431002
• Shifren JL, Davis SR, Moreau M, et al. "Testosterone Patch for the Treatment of Hypoactive Sexual Desire Disorder in Naturally Menopausal Women." Menopause. 2006. DOI: 10.1097/01.gme.0000198490.63463.dc
• Achilli C, Pundir J, Ramanathan P, et al. "Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis." Menopause. 2017;24(3):255–263. DOI: 10.1097/GME.0000000000000812
• Wierman ME, Arlt W, Basson R, et al. "Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline." J Clin Endocrinol Metab. 2014;99(10):3489–3510. DOI: 10.1210/jc.2014-2260
• Davis SR, Davison SL, Donath S, Bell RJ. "Circulating androgen levels and self-reported sexual function in women." JAMA. 2005;294(1):91–96. DOI: 10.1001/jama.294.1.91
• Vegunta S, Kling JM, Kapoor E. "Androgen Therapy in Women." J Womens Health (Larchmt). 2020;29(1):57–64. DOI: 10.1089/jwh.2018.7494
• Vlachos K, Bati N, Kaklamani I, Georgopoulos N. "Changes of androgens levels in menopausal women." Hormones (Athens). 2021;20(1):113–124. DOI: 10.1007/s42000-020-00275-x

[jeffrey]